Arcturus Therapeutics is developing portfolio of RNA therapeutics for treatment of diseases with high unmet medical needs. Our hope and vision is to build transformative, life-changing medicines for patients and their families.
Our team has extensive experience in the discovery and development of RNA medicines, as well as design and utilization of lipid-mediated drug delivery systems. This combination of in-house expertise, innovative spirit, and passion for what we do, uniquely positions us to catalyze the next generation of RNA medicines.
January 3, 2019
Arcturus Therapeutics Appoints Andrew Sassine as Chief Financial Officer
January 2, 2019
Arcturus Therapeutics to Develop ARCT-810 for Treatment of Ornithine Transcarbamylase (OTC) Deficiency
December 3, 2018
Arcturus Therapeutics to Host a Key Opinion Leader Call on Ornithine Transcarbamylase (OTC) Deficiency on December 11